Champions Oncology (CSBR) Gross Margin (2010 - 2026)
Champions Oncology (CSBR) recorded quarterly Gross Margin of 83.9% in Q1 2026, up 62.28% quarter-over-quarter from 51.7% in Q4 2025, and up 2273.0% on a YoY basis from 3.54% in Q1 2025.
Champions Oncology (CSBR) Gross Margin (2010 - 2026) Analysis & Trends
Champions Oncology's Gross Margin history runs 17 years deep, the most recent figure standing at 83.9% for Q1 2026.
- In Q1 2026, Gross Margin rose 2273.0% year-over-year to 83.9%; the TTM figure through Jan 2026 stood at 67.12% (down 2259.0% YoY), while the FY2025 annual figure was 50.15%, down 3577.0% from the prior year.
- Gross Margin was 83.9% for Q1 2026 at Champions Oncology, up from 51.7% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 207.75% in Q2 2024 to a low of 46.52% in Q2 2022.
- Historically, Gross Margin has averaged 62.48% across 5 years, with a median of 49.7% in 2024.
- The sharpest annual moves came in 2024 and 2025: Gross Margin soared 16389 bps in 2024, then slumped 16660 bps in 2025.
- A 5-year view of Gross Margin shows it stood at 47.88% in 2022, then retreated by 11 bps to 42.82% in 2023, then increased by 5 bps to 44.93% in 2024, then climbed by 15 bps to 51.7% in 2025, then surged by 62 bps to 83.9% in 2026.
- The last three Gross Margin figures came in at 83.9% (Q1 2026), 51.7% (Q4 2025), and 86.75% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 79.04% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | 83.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | 83.90% |
| Oct 31, 2025 | 51.70% |
| Jul 31, 2025 | 86.75% |
| Apr 30, 2025 | 41.15% |
| Jan 31, 2025 | 61.17% |
| Oct 31, 2024 | 44.93% |
| Jul 31, 2024 | 49.70% |
| Apr 30, 2024 | 207.75% |
| Jan 31, 2024 | 85.05% |
| Oct 31, 2023 | 42.82% |
| Jul 31, 2023 | 38.83% |
| Apr 30, 2023 | 43.86% |
| Jan 31, 2023 | 86.21% |
| Oct 31, 2022 | 47.88% |
| Jul 31, 2022 | 48.69% |
| Apr 30, 2022 | -46.52% |
| Jan 31, 2022 | 88.26% |
| Oct 31, 2021 | 86.09% |
| Jul 31, 2021 | 52.05% |
| Apr 30, 2021 | 86.07% |